Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

The One Big Beautiful Bill Act introduced a new $50 billion fund to offer rural hospitals a financial lifeline. One expert ...

Digital health engagement app Wellth raised $36 million in Series C funding to expand its “daily care motivation platform,” ...

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Stem cell transplants that are a standard treatment for certain blood cancers are out of reach for many patients. The procedure requires cells from a matched donor, but a match isn’t always available.

Now, with the ability to measure coronary inflammation through AI-enhanced CT scans and to more accurately determine a person's risk of heart attack, we can intervene earlier and more effectively.

LB Pharmaceuticals’ planned IPO will fund late-stage clinical development of LB-102, a once-daily pill designed to improve on the old Sanofi schizophrenia drug Solian. The IPO filing follow a ...

Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost ...

As operating environments become more complex, every element and system must be reliable, safe, and compliant with the web of regulations. Testing is the antidote to address these issues, however ...

Many insurers seem to be retreating from Medicare Advantage by exiting unprofitable markets and reducing benefits. This could be extremely disruptive to patients, experts warn.

If we truly believe in treating the whole patient, we must recognize that survival is not the only measure of success. Preserving a woman’s sense of self, her dignity, her identity, her autonomy ...